December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Management Of Lagophthalmos In Facial Nerve Palsy With Botulinum Toxin
Author Affiliations & Notes
  • K Boboridis
    Ophthalmology Department AHEPA University Hospital Thessaloniki Greece
  • NG Ziakas
    Ophthalmology Department AHEPA University Hospital Thessaloniki Greece
  • C Bunce
    Research and Development Moorfields Eye Hospital London United Kingdom
  • N Georgiadis
    Ophthalmology Department AHEPA University Hospital Thessaloniki Greece
  • NT Stangos
    Ophthalmology Department AHEPA University Hospital Thessaloniki Greece
  • Footnotes
    Commercial Relationships   K. Boboridis, None; N.G. Ziakas, None; C. Bunce, None; N. Georgiadis, None; N.T. Stangos, None.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 3032. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      K Boboridis, NG Ziakas, C Bunce, N Georgiadis, NT Stangos; Management Of Lagophthalmos In Facial Nerve Palsy With Botulinum Toxin . Invest. Ophthalmol. Vis. Sci. 2002;43(13):3032.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:Upper lid retraction from the unopposed levator action following Facial nerve palsy can result in severe lagophthalmos and exposure keratopathy. The available treatment modalities include lid taping, lateral tarsorrhaphy, levator complex recession and gold weight insertion. We present our experience with the use of Botulinum Toxin for weakening of the levator muscle in the management of upper lid retraction. Methods:Seven consecutive patients with short history of seventh nerve palsy and upper lid retraction were included. Vertical palpebral aperture, upper and lower lid position, sclera show, lid closure, Bell’s phenomenon and lagophthalmos were evaluated. In all cases there was inadequate lid closure with 4-7 mm lagophthalmos, paralytic lower lid ectropion with sclera show, good Bell’s phenomenon and symptomatic punctate exposure keratopathy. Botulinum Toxin (10-20 IU) was administered with a 26 G needle deep into the upper lid sulcus, above Whitnall’s ligament at the top of levator muscle. Patients were evaluated every week post treatment for a period of at least six months. Results:Lid position improved significantly in all cases within ten days from treatment. Upper lid retraction was corrected with much weaker levator function and lid position above the pupil keeping the visual axis clear. Better lid closure and less lagophthalmos helped cornea protection and cured exposure keratopathy symptoms. No ocular motility defects were noted. Facial nerve function improved spontaneously in four cases, the remaining three required repeat injection in three months time. Conclusion:Chemical denervation of levator muscle with Botulinum Toxin is a simple and effective treatment of upper lid retraction following facial nerve palsy. It offers an alternative treatment to surgery, specially in temporary nerve palsy, with optimum patient satisfaction.

Keywords: 357 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×